Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept

The major purpose of this study is to evaluate a laboratory developed test that measures multiple breast cancer-specific biomarker proteins in your blood samples. The biomarker results along with your personal medical profile will be evaluated to determine your risk for the presence of a malignancy in the breast as compared to your breast evaluation assessment conducted by your physician.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer

Detailed Description

As part of the study, 35 mL or 2 1/2 tablespoons of blood will be drawn from your arm at each study visit.

This study has 2 visits. Visit 1 will take about 1 hour. Visit 2 is a follow up visit at 6 months taking about 1 hour.

Visit 1- Screening and Blood Collection:

The following procedures will be done at the clinical research facility:

• The study doctor and/or study staff will explain the study and all the study procedures.
• You will be asked to review, sign and date this informed consent before any procedures are done.
• The study doctor and/or study staff will ask you questions about your health status and medical history and record this information.
• 35 mL or 2 ½ tablespoons of blood will be collected from your arm.
• The samples will not be labeled with your name but a unique identification code, which means they will be given a number which can be linked to you.

Visit 2 - Follow up:

If you have been diagnosed with cancer between visit 1 and visit 2, you will not be required to complete visit 2. If you have been diagnosed with LCIS or DCIS, you will be requested to return for visit 2. Otherwise you will return to the center for visit 2.

The following procedures will be performed:

• You will have a follow-up breast evaluation performed. Your follow-up breast evaluation may occur prior to Visit 2 if you have it performed at a different facility or it may be performed during this study visit.
• The study doctor and/or study staff will assess your health and medical history.
• 35 mL or 2 1/2 tablespoons of blood will be collected from your arm.
• The samples will not be labeled with your name but a unique identification code, which means they will be given a number which can be linked to you.

Your blood sample will be sent to the study Sponsor, Provista Diagnostics, Inc. for testing.

The test results will not be reported back to the study doctor and will not be used to determine or change your treatment. This testing will be done in addition to any routine testing that your study doctor performs. You will not receive the results of these tests.

Up to 350 subjects will take part in this study. Patients will be enrolled at one of seven sites.

• Study Type: Observational
• Enrollment (Anticipated): 350

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85006
      • Banner Health
  • California
    • Sacramento, California, United States, 95816
      • Sutter Institute
    • San Diego, California, United States, 92103
      • Scripps
    • Santa Barbara, California, United States, 93102-1200
      • Sansum Clinic
  • Massachusetts
    • Peabody, Massachusetts, United States, 01960
      • Lahey Clinic
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Henry Ford Hospital
  • Rhode Island
    • Providence, Rhode Island, United States, 02903
      • Rhode Island Hospital
  • South Dakota
    • Sioux Falls, South Dakota, United States, 57105
      • Avera Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 49 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Primary Care Clinics

Description

Inclusion Criteria:

• Adult women from 25 years of age to below 50 years of age
• Breast evaluation results of ACR BI-RADS® Category 3 or 4 by imaging and physicians clinical and radiological evaluation
• Study visit and blood collection within 3 weeks (21 days) of ACR BI-RADS assessment
• Patient agrees to return for diagnostic follow-up and blood collection at 6 months unless a positive cancer diagnosis is made between study visits 1 and 2. Individuals diagnosed with LCIS and DCIS will agree to return for visit 2
• Samples collected under IRB approval and Informed Consent
• Testing performed under IRB approval or waiver (as applicable)

Exclusion Criteria:

• Adults from 50 years of age or older and below 25 years of age
• Final breast evaluation results other than a ACR BI-RADS Category 3 or 4
• Subjects that have had a breast biopsy performed at any time prior to the study visit
• Samples not collected under IRB approval and Informed Consent
• Testing not performed under IRB approval or waiver (as applicable)
• Prior breast cancer diagnosis.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Breast Cancer; ACR BI-RAD Category 3 or 4 result

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Training	Part I: Establish an acceptable algorithm for generation of a single numerical score from the combination of the 5 cancer biomarkers that comprise the dtectDX-Breast Assay Part II: Define a numerical score cutoff that differentiates malignant from nonmalignant breast cancer in this population of woman.	Baseline
Blinded Validation	Demonstrate proof-of-concept for use of the dtectDx-Breast Assay to assess likelihood of breast cancer malignancy in conjunction with the physicians clinical and radiological evaluations.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Sensitivity/Specificity	Demonstrate the numerical score, collaborated via proprietary algorithm (greater then 60 is an elevated score, less then 60 is a normal score), for the dtectDx-Breast Assay increases the likelihood of malignant breast cancer detection when used adjunctively with the assessment of BI-RADS Categories 3 and 4 compared to the assessment of BI-RADS Categories 3 and 4 alone.	Baseline

Collaborators and Investigators

• Sponsor: Provista Diagnostics, Inc

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start: March 1, 2013
• Primary Completion (Actual): June 1, 2014
• Study Completion (Anticipated): August 1, 2014

Study Registration Dates

• First Submitted: April 5, 2013
• First Submitted That Met QC Criteria: April 19, 2013
• First Posted (Estimate): April 24, 2013

Study Record Updates

• Last Update Posted (Estimate): June 9, 2014
• Last Update Submitted That Met QC Criteria: June 6, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Keywords: Ultrasound; Breast Cancer; Cancer; Imaging; Biomarkers; Mammogram; Woman; ACR BI RAD Category 3; ACR BI RAD Category 4
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: dtectDx-Breast-001; ProvistaDx (Other Identifier: ProvistaDx)